True adherence with the Turbuhaler in young children with asthma

Archives of Disease in Childhood

Volumn 96, Issue 2, 2011, Pages 168-173

  Nikander, K ^a   Turpeinen, M ^b   Pelkonen, A S ^b   Bengtsson, T ^c   Selroos, O ^d   Haahtela, T ^b  

^a PHILIPS HEALTHCARE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AsraZeneca R and D   (Sweden)

^d Semeco AB ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; PLACEBO;

ARTICLE; ASTHMA; CHILD; CHILDHOOD DISEASE; DOUBLE BLIND PROCEDURE; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; METERED DOSE INHALER; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SPIROMETER; SYMPTOM; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; AGE FACTORS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; PEAK EXPIRATORY FLOW RATE; SELF ADMINISTRATION; SELF EFFICACY;

EID: 78651452965     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.187724     Document Type: Article

References (26)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2008. www.ginasthma.com (accessed 6 August 2009).
2. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008 ; 63 (Suppl 4): iv1-121.
3. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother 1996 ; 6 :273-99
4. Borgström L, Asking L, Beckman O, et al. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler. J Aerosol Med 1998 ; 11 (Suppl 1): S59-64.
5. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med 1999 ; 93 : 763-9.
6. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: Areview of literature. J Behav Med 2008 ; 31 : 213-24.
7. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992 ; 67 : 332-3.
8. Cerveri I, Locatelli F, Zoia MC, et al. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999 ; 14 : 288-94.
9. Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin 2005 ; 21 (Suppl 4): S33-7.
10. Rand CS. Non-adherence with asthma therapy: more than just forgetting. J Pediatr 2005 ; 146 : 157-9.
11. Ulrik CS, Backer V, Søes-Petersen U, et al. The patient's perspective: adherence or non-adherence to asthma controller therapy? J Asthma 2006 ; 43 : 701-4.
12. Partridge MR. The asthma consultation: what is important? Curr Med Res Opin 2005 ; 21 (Suppl 4): S11-7 .
13. Charles T, Quinn D, Weatherall M, et al. An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. J Allergy Clin Immunol 2007 ; 119 : 811-6.
14. H orn C R, Clark TJ, Cochrane GM. Compliance with inhaled therapy and morbidity from asthma. Respir Med 1990 ; 84 : 67-70.
15. Nikander K, Arheden L, Denyer J, et al. Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system. J Aerosol Med 2003 ; 16 : 273-81.
16. Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008 ; 93 : 654-9.
17. Dolovich MB, Vanzieleghem M, Hidinger K-G, et al. . Influence of inspiratory flow rate on the response to terbutaline inhaled via the Turbuhaler (abstract). NER Allergy Proc 1988 ; 9 : 380.
18. Newman SP, Morén F, Trofast E, et al. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharmaceut 1991 ; 74 : 209.
19. Engel T, Scharling B, Skovsted B, et al. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol 1992 ; 33 : 439-44.
20. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990 ; 65 : 308-10.
21. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr 1998 ; 157 : 1017-22.
22. Crompton GK, Barnes PJ, Broeders M, et al. Aerosol Drug Management Improvement Team. The need to improve inhalation technique in Europe: Areport from the Aerosol Drug Management Improvement Team. Respir Med 2006 ; 100 : 1479-94.
23. Fiese BH, Wamboldt FS, Anbar RD. Family asthma management routines: connections to medical adherence and quality of life. J Pediatr 2005 ; 146 : 171-6.
24. Everard ML. Role of inhaler competence and contrivance in "difficult asthma". Paediatr Respir Rev 2003 ; 4 : 135-42.
25. Crompton GK, ed. Turbuhaler Inhalation System. Oxford, UK: Oxford Clinical Communication, 1993.
26. Jentzsch NS, Camargos PA, Colosimo EA, et al. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy 2009 ; 64 : 1458-62.